Moreover, sorafenib can also affect tumor angiogenesis through VEGFR and PDGFR inhibition, and different studies have shown that co-treatment of EGFR-TKIs with antiangiogenic drugs can improve progression-free survival of NSCLC patients76–78. Here, EGFR is linked to neoplasm.